Latest Articles
-
How Merck Gets To $51 Billion: Oncology or Vaccines?
Merck (NYSE:MRK) revenue grew from $39.8 billion in 2016 to $46.8 billion in 2019, and it is estimated to top $51.5 billion in 2020, primarily driven by its oncology drug, Keytruda, according to our estimates. The company’s oncology drugs will a...
-
Is Merck A Good Buy At Current Levels?
Going by trends seen during the 2008 slowdown, Merck (NYSE: MRK) appears to be a good buy at the current levels of under $75, and it could outperform the broader S&P 500 index, when the coronavirus and oil price war crisis winds down. We saw...
-
Merck Q4 Earnings Preview: Can MRK Beat Average Consensus Earnings?
Merck is slated to release its Q4 and full-year 2019 results on February 5, 2020. We don’t expect the company to beat, but rather meet, the average consensus EPS of $5.17. For full year 2019, Trefis estimates that the company will report: ...
-
How Much Revenue Does Merck Generate From The United States?
Merck (NYSE:MRK) generates its revenue primarily from sales of pharmaceutical products. The company generated $18 billion in sales in the United States, accounting for over 40% of its total revenue in 2018. This figure has been on a decline and ...
-
What’s Fueling Merck’s Stock Price Growth?
Merck’s (NYSE:MRK) stock price grew over 50% from around $56 levels in 2017 to around $84 in 2019, primarily driven by revenue growth and expansion of the P/E multiple. Merck’s stock price growth was higher than <10% growth seen f...
-
Merck’s $3 Billion Drug Jumped To 4x Growth Over Previous Year
Merck’s (NYSE:MRK) Gardasil is the leader in the human papillomavirus (HPV) vaccines market. HPV is a group of more than 200 related viruses, of which several are spread through direct sexual contact. HPV can cause cervical, anal, orophary...
-
Merck’s Leadership In HPV Vaccines Market
Merck’s (NYSE:MRK) Gardasil is the leader in the human papillomavirus (HPV) vaccines market. HPV is a group of more than 200 related viruses, of which several are spread through direct sexual contact. HPV can cause cervical, anal, orophary...
-
How Important Is Keytruda For Merck?
Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and melanoma among others. It has become the most...
-
Will Merck’s #1 Therapeutic Area With $10 Billion In Revenue Grow?
Merck’s (NYSE:MRK) anti-infectious drugs business is the company’s largest therapeutic area and it will likely decline in low-single-digits from about $10.9 billion in 2018 to $10.4 billion in 2021, according to Trefis estimates. Thi...
-
How Much Can Merck’s Oncology Drugs Revenue Grow Over The Next Three Years?
Merck’s (NYSE:MRK) oncology drugs’ revenue could grow at a CAGR of 10.3% from $8.24 billion in 2018 to $10.95 billion in 2021, according to Trefis estimates. This growth will likely be led by higher sales of Keytruda, as well as high...
-
Merck’s Q1 Earnings Beat Led By Keytruda, And The Momentum Could Continue In The Near Term
Merck (NYSE:MRK) recently reported its Q1 2019 results, which were above our estimates. This note details the company’s Q1 performance, and Trefis’ forecasts for the full year 2019. You can view our interactive dashboard analysis ~ How Did Merck...
-
Merck’s Q1 Earnings Growth Will Likely Be Led By Higher Keytruda Sales
Merck (NYSE:MRK) is expected to publish its Q1 2019 results on April 30. This note details Trefis’ forecasts for Merck, as well as some of the key trends we will be watching when the company reports earnings. You can view our interactive dashboar...
-
How Much Can Merck’s Share Price Grow If Keytruda Gets 10% Share Of Oncology Drug Market?
Merck’s (NYSE:MRK) Keytruda has been on a strong run with sales exceeding $7 billion in 2018. This can be attributed to its superior benefits in lung cancer, and various regulatory approvals for multiple indications. While the drug’s ...
-
Merck’s Q4 Earnings And What Lies Ahead For The Company In 2019
Merck (NYSE:MRK) recently reported its Q4 2018 earnings, which were slightly below our estimates. The company’s top line and bottom line grew in mid-single-digits in Q4, led by a continued ramp up in Keytruda, and Gardasil sales. Looking fo...
-
Expect Keytruda & Gardasil To Drive Merck’s Q4 Earnings Growth
Merck (NYSE:MRK) is set to report its Q4 2018 earnings on February 1, and we expect the company to post mid-single-digit top line growth and low double-digits earnings growth. This can be attributed to the continued growth in the company’s ...
